Anemia
From the Journals
Genetic testing helps avoid false hemoglobinopathy diagnoses in newborns
“We now perform simultaneous protein-based and genetic testing as our standard clinical practice.”
From the Journals
Flow-mediated dilation of brachial artery predicts renal dysfunction in sickle cell disease
Conference Coverage
Deferiprone noninferior to deferoxamine for iron overload in SCD, rare anemias
An oral iron chelator granted accelerated approval for thalassemia is noninferior to deferoxamine for iron overload in patients with sickle cell...
Conference Coverage
Sevuparin failed for acute VOC in sickle cell, but may have preventive potential
The novel nonanticoagulant heparinoid drug sevuparin may have value in the setting of prodromal vaso-occlusive crisis in patients with SCD.
Commentary
The evolving landscape of complement inhibition therapy
The surge of new complement inhibitors could revolutionize our strategy for treatment of autoimmune-mediated diseases.
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
ASH releases guidelines on managing cardiopulmonary and kidney disease in SCD
ORLANDO – ASH has released the first of five new sets of sickle cell disease guidelines, with the first focusing on screening and management of...
Conference Coverage
Sutimlimab boosts hemoglobin, quality of life in cold agglutinin disease
ORLANDO – A novel antibody targeted to the complement pathway increased hemoglobin and improved quality of life in patients with cold agglutinin...
Conference Coverage
Think twice: Choosing Wisely recommendations on testing to avoid in pediatric hematology
ORLANDO – The list, which was released by ASH and the American Society of Pediatric Hematology/Oncology, includes five unnecessary tests or...
Conference Coverage
Oral arginine emerges as potential adjuvant for vaso-occlusive crisis management
ORLANDO – Researchers called for a phase 3, multicenter clinical trial to further evaluate the treatment.
Conference Coverage
NFIX could be a target for sickle cell therapy
ORLANDO – Preclinical research suggests it may be a fetal hemoglobin repressor.